Import Inspection of Certain Products Supervised by the Ministry of Health

Regulatory Scope – Annex-Based Product Classification Drives the Entire Process

The Communiqué, published in the Official Gazette dated 31 December 2025, applies to products listed under Annex-1/A, Annex-1/B, Annex-1/C, and Annex-2, all of which are subject to conformity inspection for human health and safety under the supervision of the Ministry of Health.

These product groups typically include:

• Pharmaceutical inputs and raw materials
• Health-related chemical substances
• Public health-related products
• Inputs used in specialized food or medical formulations

The key operational implication is that each annex category carries different documentation requirements, reporting obligations, and regulatory expectations, meaning that incorrect annex classification at the beginning of the process can invalidate the entire import structure.

This makes classification not only a customs function but a regulatory decision that directly determines compliance requirements, often requiring structured alignment through HS code classification.

How the System Works – Control Certificate as a Pre-Import Gate

The core of the Communiqué is the requirement to obtain a Control Certificate before importation, which acts as a mandatory pre-condition for customs clearance.

The process operates as follows:

• The importer submits an application to the Ministry of Health before shipment
• Required documents are evaluated, including analysis and health certificates
• If approved, a Control Certificate is issued
• The certificate is presented at customs during declaration registration

The Control Certificate:

• Is generally valid for 12 months
• Is tied to product specifications, origin, and exporter
• May be reused for repeat imports under identical conditions

However, this apparent flexibility creates a hidden risk: any change in product characteristics, origin, or supplier invalidates the basis for reuse and requires a new application.

In addition, for certain products falling under special authorization regimes, the rules of special permit substances control may apply, further increasing complexity.

Practical Impact – Upstream Document Preparation and Timing Dependency

From an operational perspective, the most critical shift introduced by this Communiqué is that compliance must be fully established before shipment, not corrected at the border.

The required documentation typically includes:

• Application petition
• Invoice or proforma invoice
• Certificate of Analysis (for relevant annex categories)
• Health Certificate issued by the competent authority of the exporting country
• Official translations of required documents

Because the Control Certificate is issued based on these documents, any inconsistency or incompleteness results in delays or rejection before shipment can even proceed.

This creates a front-loaded compliance burden where:

• Supplier coordination becomes critical
• Laboratory and authority-issued documents must be secured in advance
• Translation processes must be integrated into timelines

Risk Areas – Annex Misclassification and Document Integrity

The most significant compliance risk under this Communiqué arises from incorrect annex classification and weak document integrity.

Common failure scenarios include:

• Misclassification of products across Annex-1/A, 1/B, 1/C, and Annex-2
• Missing or incomplete analysis certificates
• Health certificates that do not meet format or authority requirements
• Inconsistencies between invoice data and technical documentation

In addition, authorities may request additional documents at any stage, meaning that incomplete preparation can lead to unpredictable delays.

Another critical risk is document authenticity; if any document is found to be:

• Not issued by the relevant authority
• Incorrectly translated
• Inconsistent with product identity

the application may be rejected regardless of other compliance elements.

Compliance and Audit Impact – Post-Import Reporting as a Critical Control Point

One of the most important—and often underestimated—features of this Communiqué is the introduction of strict post-import reporting obligations.

Importers must submit electronic notifications to TİTCK within defined deadlines:

• Within 15 days for products under Annex-1 categories
• Within 30 days for certain pharmaceutical inputs and specialized products
• Within 30 days for inputs used in foods for special medical purposes

These reporting requirements include submission of:

• Customs declaration data
• Invoice copies
• Additional supporting information via electronic systems

From a practical perspective, this creates a second compliance checkpoint after customs clearance, where failure to meet deadlines can trigger enforcement actions.

This reflects Türkiye’s broader compliance approach, where control continues beyond import through mechanisms such as customs audit.

Strategic Actions – Building a Closed-Loop Compliance Workflow

From a professional customs advisory perspective, imports under this Communiqué must be managed through a closed-loop compliance workflow covering both pre-import and post-import stages.

Companies should:

• Confirm correct annex classification before application
• Align all documentation with product specifications and regulatory requirements
• Establish internal controls for document verification and translation
• Implement tracking systems for post-import reporting deadlines
• Ensure coordination between customs, regulatory, and operational teams

In addition, companies should treat post-import reporting not as an administrative task but as a critical compliance obligation that must be integrated into operational workflows.

For companies managing complex import structures, aligning these processes through customs consulting can significantly reduce compliance risk.

Professional Assessment – Lifecycle Compliance Determines Risk Exposure

From a senior customs consultancy standpoint, Communiqué 2026/20 represents a clear shift toward lifecycle-based compliance, where regulatory obligations are distributed across multiple stages of the import process.

The key differentiator in this regime is that:

• Compliance begins before shipment
• Continues through customs clearance
• Extends into post-import reporting

In this environment:

• Errors are rarely legal—they are procedural
• Risks arise from process gaps, not regulatory ambiguity
• Compliance depends on internal coordination and discipline

For companies operating across global supply chains, this reinforces the need for integrated compliance strategies, as discussed in globalization and consultancy.

Conclusion – Health-Controlled Imports Require End-to-End Compliance Management

Communiqué 2026/20 confirms that imports of health-supervised products into Türkiye operate under an end-to-end compliance model where success depends on accurate classification, complete documentation, and strict adherence to post-import reporting obligations.

This transforms these imports into controlled processes where failure at any stage—before shipment, at customs, or after clearance—can result in operational disruption and regulatory exposure.

Official Gazette Reference

The official legal text is only available in Turkish; however, the key regulatory framework and practical implications are fully explained above.

See the legislation document.